Redeye provides a short comment on the trading update from Cheffelo released earlier this morning.
Q1e: clean EBIT of ~SEK -45m, Q2 likely better Pulp prices up, but futures point down Fair value ran...
Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInve...
Redeye sees an interesting opportunity in Transtema, which is trading close to its four-year low des...
Global efterfrågan driver tillväxtmöjligheter LifeClean verkar på en växande marknad där skärpta kra...
Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by Next...
Relais announced today that it will acquire a majority stake in Matro Group, a well-established dist...
Report out 29 April No major machine deliveries in Q1e Minor est.
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
Mangold återupptar bevakning av investmentbolaget Archelon Natural Resources "Archelon".
The Board of Directors proposes an additional one-time extra dividend of SEK0.
Redeye provides a research note on Faron Pharmaceuticals following the announcement of a convertible...
Q1 report due 29 April We forecast net sales of SEK 589m, EBITA of SEK 92m We lower '25e-'27e EBITA ...
Lipigon har vidtagit åtgärden för att skynda på rekryteringen till bolagets fas 2-studie som dragit ...
Redeye initiates coverage of Tradedoubler, a leading digital network within affiliate and influencer...
